MPH15 Apr 2019 08:40
Every little step forward should be seen positively
London, 15 April 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces that it has held a successful Type B end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding acumapimod (BCT-197) as a treatment for the reduction of acute exacerbations of COPD (AECOPD).